Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou Sells 6,893 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou sold 6,893 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $48.88, for a total transaction of $336,929.84. Following the sale, the executive vice president now owns 118,388 shares in the company, valued at $5,786,805.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Rong Zhou also recently made the following trade(s):

• On Monday, August 26th, Rong Zhou sold 4,000 shares of Amphastar Pharmaceuticals stock. The stock was sold at an average price of $48.35, for a total value of $193,400.00.

Amphastar Pharmaceuticals Stock Down 4.7 %

Shares of NASDAQ:AMPH opened at $45.48 on Thursday. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92. The company has a market capitalization of $2.19 billion, a PE ratio of 15.16, a P/E/G ratio of 0.92 and a beta of 0.82. The company’s fifty day moving average is $48.42 and its 200-day moving average is $44.34. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43.

Institutional Trading of Amphastar Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Silvercrest Asset Management Group LLC boosted its stake in shares of Amphastar Pharmaceuticals by 35.1% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 112,428 shares of the company’s stock valued at $4,937,000 after purchasing an additional 29,182 shares during the last quarter. International Assets Investment Management LLC bought a new position in shares of Amphastar Pharmaceuticals during the third quarter worth about $11,070,000. Intech Investment Management LLC bought a new stake in shares of Amphastar Pharmaceuticals in the second quarter worth $426,000. Granite Investment Partners LLC boosted its stake in shares of Amphastar Pharmaceuticals by 12.7% during the 2nd quarter. Granite Investment Partners LLC now owns 397,514 shares of the company’s stock worth $15,901,000 after buying an additional 44,744 shares during the last quarter. Finally, 1620 Investment Advisors Inc. acquired a new stake in shares of Amphastar Pharmaceuticals in the second quarter valued at about $93,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Analyst Upgrades and Downgrades

AMPH has been the subject of a number of research reports. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Finally, Piper Sandler dropped their target price on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $63.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.